Yuri Kamitsuji

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

Shinya Kimura, Haruna Naito, Hidekazu Segawa et al. · Blood · 2005 · 244 citations · Full text

Medicine, Oncology, Pharmacology +7

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity

Asumi Yokota, Shinya Kimura, Satohiro Masuda et al. · Blood · 2006 · 103 citations · Full text

Medicine, Oncology, Pharmacology +13

ABT‐737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug‐resistance mechanisms

Junya Kuroda, Shinya Kimura, Michael Andreeff et al. · British Journal of Haematology · 2007 · 84 citations

Medicine, Oncology, Pharmacology +17

Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation

Motonobu Watanabe, Souichi Adachi, Hiroshi Matsubara et al. · International Journal of Cancer · 2008 · 72 citations · Full text

Life Sciences, Cell Biology, Oncology +17